EAST COAST ONCOLOGY & NUCLEAR MEDICINE UPDATE 2023 (ECONM) 1 & 2 N O V E M B E R 2 0 2 3 H - E L I T E D E S I G N H O T E L , K O T A B H A R U EAST COAST ONCOLOGY SOCIETY O R G A N I Z E D B Y : D E P A R T M E N T O F N U C L E A R M E D I C I N E , R A D I O T H E R A P Y & O N C O L O G Y H O S P I T A L U N I V E R S I T I S A I N S M A L A Y S I A K U B A N G K E R I A N , K E L A N T A N . PROGRAM BOOK NNEEWW DDIIMMEENNSSIIOONN OOFF CCAANNCCEERR CCAARREE C O L L A B O R A T I O N W I T H : E A S T C O A S T O N C O L O G Y S O C I E T Y ( E C O S )
E A S T C O A S T O N C O L O G Y & N U C L E A R M E D I C I N E U P D A T E 2 0 2 3 ( E C O N M ) N EW D I M E N S I O N O F C A N C E R C A R E 0 1 & 0 2 N O V E M B E R 2 0 2 3 H - E L I T E H O T E L , K O T A B H A R U Organized by: DEPARTMENT OF NUCLEAR MEDICINE, RADIOTHERAPY & ONCOLOGY HOSPITAL UNIVERSITI SAINS MALAYSIA KUBANG KERIAN, KELANTAN. Collaboration with: EAST COAST ONCOLOGY SOCIETY (ECOS)
CONTENTS TABLE OF Organizing Committee Welcoming Message from Head of Department Welcoming Message from Chairman ECONM 2023 Program Itinerary Faculty & Panels of Speakers Conference Venue Floor Plan The Sponsors Objectives Sponsored Tea & Lunch Symposium Talk Abstract of Poster 1 3 4 5 6 9 11 18 19 20 24
COMMITTEE OEGANIZING Patron Prof. Dato’ Dr. Nik Hisamuddin Nik Ab. Rahman Advisor Dr. Norazlina Binti Mat Nawi Dr. Wan Mohd Nazri Bin Wan Zainon 1. 2. Chairman Dr. Wan Fatihah Binti Wan Sohaimi Vice Chairman 1. Dr. Ahmad Lutfi Bin Yusoff 2. Dr. Elyana Binti Razalle Secretary Dr. Nurhanani Binti Suhaimi Assistant Secretary Pn. Rapia’ah Binti Ismail Treasurer Pn. Ilyana Binti Ab Aziz Assistant Treasurer Dr. Farahwahida Binti Md Yusof Scientific Committees Dr. Ahmad Lutfi Bin Yusoff Dr. Wan Mohd Nazri Bin Wan Zainon Dr. Elyana Binti Razalle Dr. Shahrizal Bin Mustaffa Dr. Farahwahida Binti Md Yusof Dr. Nurhanani Binti Suhaimi Dr. Ezma Yanis Binti Mohd Mahidin Dr. Aienuddin Husairi Bin Hussain Dr. Mohd Arif Saifudin Bin Sulong Dr. Nurfarahiyah Binti Mohd Yunus Dr. Suhailah Binti Badruddin Dr. Muhammad Azizul Bin Mohd Daud Dr. Nurul Syamimi Binti Suhaimi Dr. Nik A’isyah Binti Nik Mohd Zaid 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. Promotion & Website 1. Dr. Mohd Arif Saifudin Bin Sulong 2.En. Muhammad Yusri Bin Udin 3.En. Ahmad Thaifur Bin Khaizul 1 Dr. Shahrizal Bin Mustaffa En. Reduan Bin Abdullah En. Mohamad Dzulhilmi Bin Mohamad Kamarulzaman 1. 2. 3. Sponsorship Registration 1. Dr. Aienuddin Husairi Bin Hussain 2. Dr. Suhailah Binti Badruddin 3. Pn. Norhidayah Binti Mohmad Diah
Protocol Dr. Nurul Syamimi Binti Suhaimi Dr. Nik A’isyah Binti Nik Mohd Zaid Pn. Siti Norma Binti Ibrahim Pn. Fatin Nur Syuhada Binti Ruslan 1. 2. 3. 4. Accommodation & Hospitality Dr. Ezma Yanis Binti Mohd Mahidi Dr. Muhamad Azizul Bin Mohd Daud Pn. Siti Norma Binti Ibrahim 1. 2. 3. Graphic and Publication En. Mohammad Zaid Bin Samsudin En. Mohd Sazarman Bin Mohamad Salleh 1. 2. Program Book En. Muhammad Yusri Bin Udin Dr. Mohd Arif Saifudin Bin Sulong Dr. Farahwahida Binti Md Yusof 1. 2. 3. Technical/AVA En. Mohammad Zaid Bin Samsudin En. Ahmad Thaifur Bin Khaizul En. Mohd Sazarman Bin Mohamad Salleh 1. 2. 3. Gift & Souvenir Dr. Nurfarahiyah Binti Mohd Yunus Dr. Nurhanani Binti Suhaimi Pn. Fatin Nur Syuhada Binti Ruslan Pn. Azirah Binti Ibrahim 1. 2. 3. 4. Food & Arrangement Pn. Ariza Binti Hassan Pn. Nurul Huda Binti Senin 1. 2. Transportation En. Nik Mohd Mustakim Bin Nik Zahari En. Mohd Nasaruddin Bin Yusoff 1. 2. Booth & Poster Arrangement En. Nik Mohd Mustakim Bin Nik Zahari En. Mohd Nasaruddin Bin Yusoff En. Reduan Bin Abdullah En. Mohamad Dzulhilmi Bin Mohamad Kamarulzaman 1. 2. 3. 4. Emcee Dr. Elyana Binti Razalle Dr Siti Mariam Binti Yacob 1. 2. 2 Onsite Registration Pn. Norhidayah Binti Mohmad Diah Pn. Rapia’ah Binti Ismail En. Reduan Bin Abdullah En. Mohamad Dzulhilmi Bin Mohamad Kamarulzaman Pn. Ilyana Binti Aziz Pn. Azirah Binti Ibrahim 1. 2. 3. 4. 5. 6.
Multidisciplinary OBJECTIVE Collaboration: Encourage collaboration between Oncologists, Radiologists, Nuclear Medicine specialists, and other healthcare professionals to improve patient care and outcomes. Sharing latest updates in management of Oncology & Nuclear Medicine. To create wonderful networking while gaining meaningful educational experience from professional cancer care community. To create a platform & great opportunity for abstract and poster presentation in Oncology and Nuclear Medicine 3
Distinguished Guests, Delegates, and Colleagues, It brings me great honour and privilege to welcome all to join the East Coast Oncology & Nuclear Medicine Update 2023, held in Kota Bharu, a city rich in Malay customs and Islamic heritage. I would like to thank all of the invited speakers for their contributions to this seminar and for sharing their rich expertise on the newest breakthroughs in multidimensional cancer care with all of the attendees. The goal of this seminar is to bring the participants up to speed with the latest developments in cancer management. Cancer management is continually evolving, and all medical practitioners must understand the paradigm shift in cancer care for the benefit of patients. To all delegates, please take advantage of this meeting to network and learn from the best in our region. I would like to take this opportunity to thank all the members of the organizing committee for their tireless effort and support in making this event a success. Last but not least, we would like to express our sincere gratitude to all of our sponsors for their generous support and cooperation throughout this event. Thank you, and have a great meeting. MESSAGE WELCOMING Dr Norazlina Mat Nawi Head of Department Nuclear Medicine, Radiotherapy & Oncology Hospital USM 4
Dear Colleagues and Friends, It is my honour to welcome all the speakers, delegates ang guest of the East Coast Oncology and Nuclear Medicine (ECONM) Update 2023. This program is organized by the Department of Nuclear Medicine, Oncology and Radiotherapy, Hosp USM in collaboration with the Persatuan Onkologi Pantai Timur (ECOS - East Coast Oncology Society). Previously, known as the 'East Coast Oncology Update - ECOU) Seminar which has been held in 2016 and 2018 but was subsequently disrupted when the country experienced the Covid-19. For this year, East Coast Oncology & Nuclear Medicine (ECONM) Update 2023 seminar aims to highlight the current advancement and incredible in the field of oncology and nuclear medicine. It will be a venue for sharing diversity of opinions on cancer care and theranostic of Nuclear Medicine. It is hope that the present of our distinguished speakers will spur a lot of interest in the advancement of cancer care to the medical practitioners and allied health colleagues for the betterment of our services to the patients. As the Chairman of organizing committee, I would like to thank to my committee members for their hard work and endless support in making sure that this seminar meets a great success. It is hoped that this spirit can be continued in the coming years. I would like to express my greatest gratitude to the sponsors and contributors, without which the seminar would not have been a hit. Last but not least to our Director of Hosp USM, Dean of School of Medical Sciences, and Head of Department. Dr Wan Fatihah Wan Sohaimi MESSAGE WELCOMING Chairman East Coast Oncology & Nuclear Medicine Update (ECONM) 2023 5
DAY 1: 01 November 2023 SYMPOSIUM 01 (BREAST ENDOCRINE) OPENING & OFFICIATING CEREMONY ITINERARY program 0800-0830 REGISTRATION 0830-0900 NEW APPROACH FOR SURGICAL MANAGEMENT OF BREAST CANCER Assoc Prof Dr Maya Mazuwin Binti Yahya 0900-0930 TNBC TREATMENT UPDATE Dr Ibtisam Binti Muhamad Nor 0935-0940 OPENING SPEECH CEREMONY Dr Norazlina Binti Mat Nawi Head of Department of Nuclear Medicine, Radiotherapy & Oncology, Hospital USM 0940-0950 INAUGURAL SPEECH AND OPENING CEREMONY Profesor Dr Mohd Imran Bin Yusof Deputy Director (Operation), Hospital USM 0950-1000 PHOTO SESSION/ POSTER EXHIBITION/ BOOTH OPENING & VISIT 1000-1030 TEA BREAK SYMPOSIUM 01 ALK+NSCLC: MAXIMISING THE POTENTIAL FOR PATIENTS THROUGHOUT THEIR TREATMENT JOURNEY Dr Azza Binti Omar Sponsored by Pfizer (Malaysia) Sdn. Bhd. 0930-0935 DOA RECITATION 61030-1100 HR+/HER2- TREATMENT UPDATE Dr Ibtisam Binti Muhamad Nor Sponsored by Celltrion Healthcare 1100-1130 HER2+ TREATMENT UPDATE Dr Eznal Izwadi Bin Mohd Mahidin Sponsored by Roche (Malaysia) Sdn. Bhd.
1200-1300 LUNCH BREAK SYMPOSIUM 01 OlympiA: Transforming Treatment Management of HER2-Negative Early Breast Cancer with Targeted Therapy Dr Azura Binti Deniel Top Defining PACIFIC as Standard of Care with Unprecedented Survival in Unresectable Stage 3 NSCLC Following CRT Dr Azza Binti Omar Sponsored By AstraZeneca Sdn. Bhd. CASE & CLINICAL PRESENTATION 1130-1200 Case Presentation & Discussion Moderator: Dr Wan Mohd Nazri Bin Wan Zainon Panelist : 1) Dr Ibtisam Binti Muhamad Nor 2) Dr Eznal Izwadi Bin Mohd Mahidin 1300-1400 BREAK 7 SYMPOSIUM 02 (LUNG) 1400-1430 TARGETED THERAPY BASED ON MOLECULAR PROFILING IN NSCLC Dr Azza Binti Omar 1430-1500 UPDATE ON IMMUNO-ONCOLOGY THERAPY FOR NSCLC Dr Azza Binti Omar Sponsored by Merck Sharp & Dohme (Malaysia) Sdn. Bhd. 1500-1530 SMALL-CELL LUNG CANCER Dr Eznal Izwadi Bin Mohd Mahidin 1530-1600 PET-CT UPDATE IN BREAST AND LUNG CANCER Dr Muhammad Adib Bin Abdul Onny 1600-1630 TEA BREAK SYMPOSIUM 02 THE MATURING TREATMENT LANDSCAPE OF mHSPC Dr Wan Mohd Nazri Bin Wan Zainon Sponsored by Astellas Pharma Malaysia Sdn. Bhd 1630 END OF DAY 1
8 DAY 2: 02 November 2023 SYMPOSIUM 03 (HEAD AND NECK) 0820-0830 REGISTRATION 1030-1050 TEA BREAK & BOOTH VISIT 0830-0900 DIFFERENTIATED THYROID CANCER: NUCLEAR MEDICINE MANAGEMENT PERSPECTIVE Dr Wan Fatihah Binti Wan Sohaimi 0900-0930 HEAD AND NECK CANCER: SURGICAL PERSPECTIVE Assoc Prof Dr Norhafiza Binti Mat Lazim 0930-1000 SYSTEMIC THERAPY AND IMMUNOTHERAPY UPDATE FOR HEAD AND NECK CANCER Dr Nisha Binti Mohd Shariff 1000-1030 ROLE OF BRACHYTHERAPY AND RADIOTHERAPY IN HEAD AND NECK CANCER Assoc Prof Dr Gokula Kumar a/l Appalanaido SYMPOSIUM 04 (THERANOSTIC NUCLEAR MEDICINE) 1050-1120 PIGMENTED VILLONODULAR SYNOVITIS -PVNS (DIAGNOSIS, SURGICAL INTERVENTION AND OUTCOME) Prof Dr Wan Faisham Nu’man Bin Wan Ismail 1120-1150 RADIOSYNOVECTOMY IN PIGMENTED VILLONODULAR SYNOVITIS-PVNS Dr Norazlina Binti Mat Nawi 1150-1220 RELEVANCE OF SPECT-CT IN NUCLEAR NEUROLOGY IN THE ERA OF PET-CT Dr Kamalia Binti Kamarulzaman 1220-1320 LUNCH BREAK SYMPOSIUM 04 THE ROLE OF LENVATINIB IN UNRESECTABLE OF HCC Dr Ibtisam Binti Muhamad Nor Sponsored by Eisai (Malaysia) Sdn. Bhd. 1320-1330 AWARD CEREMONY & LUCKY DRAW 1330 CLOSING CEREMONY Dr Wan Fatihah Binti Wan Sohaimi Chairman ECONM 2023
9SYMPOSIUM TALK sponsored TEA & LUNCH TEA BREAK SYMPOSIUM 01 (10AM-10.30AM, 1 NOVEMBER 2023) TEA BREAK SYMPOSIUM 01 (4PM-4.30PM, 1 NOVEMBER 2023)
10LUNCH BREAK SYMPOSIUM 01 (12PM-1.00PM, 1 NOVEMBER 2023) SYMPOSIUM TALK sponsored TEA & LUNCH LUNCH BREAK SYMPOSIUM 04 (12.20PM-1.20PM, 2 NOVEMBER 2023)
OF SPEAKER FACULTY & PANEL 11
Associate Professor Dr Maya graduated her degree from University College Cork, Ireland in 1999. Then, she completed her master of medicine in general surgery under Universiti Sains Malaysia in 2006. Her field of interest is in breast and endocrine surgery and she has been actively involved in multiple research area including breast cancer, thyroid cancer and parathyroid adenoma. Assoc Prof Dr Maya Mazuwin Binti Yahya Consultant Breast & Endocrine Surgeon/Lecturer Department of Surgery, School of Medical Science USM Dr Ibtisam obtained her undergraduate degree from Royal College of Surgeon in Ireland (RCSI), Dublin, Ireland in 2001 and completed her postgraduate Master in Clinical Oncology from University Malaya in 2012. She is now Deputy Head of Radiotherapy and Oncology Department General Hospital Kuala Lumpur. Her special interest is in dental, upper GI, breast, gynaecological and colorectal cancer and one of the specialist leading the total body irradiation and total skin electron treatment. She is also a supervisor and examiner for Master in Oncology programme in UMMC and actively involved in ISR trials. Dr Ibtisam Binti Muhamad Nor Consultant Clinical Oncologist Department of Radiotherapy & Oncology, Hospital Kuala Lumpur 12
Dr Eznal Izwadi Mohd Mahidin, graduated with MD from UPM, in 2007. He served the first 3 years of his career in Kelantan, mainly in Hopital Raja Perempuan Zainab II, before moving to Kuala Lumpur and joining Radiotherapy and Oncology Dept HKL in 2010. He obtained his Masters in Clinical Oncology from University Malaya in 2016 and currently a Clinical Oncologist at the Radiotherapy and Oncology Department in Hospital Kuala Lumpur. His areas of interest are in breast, head and neck radiation, gynaecological and lung malignancies. He is involved in several clinical trials of various tumour sites and also part of the group developing the Malaysian CPG for the Management of Breast Cancer, 3rd Edition. Dr Eznal Izwadi Bin Mohd Mahidin Clinical Oncologist Department of Radiotherapy & Oncology Hospital Kuala Lumpur Dr Azza Binti Omar Consultant Respiratory Medicine Department of Medicine Hospital Raja Perempuan Zainab II Dr Azza Omar is a Respiratory Physician in Hospital Raja Perempuan zainab II in Kelantan, Malaysia. She graduated in Medicine from Universiti Sains Malaysia in 1999 and 2008 received a Master’s Degree in Internal Medicine in the same university. Later, she continued her fellowship in respiratory in various hospitals in Malaysia. Her main interest lies in Lung Oncology, Asthma and COPD. Dr Azza Omar ia a member of the developing committee for Malaysian CPG Asthma and actively involved in both Malaysian Thoracic Society (MTS), Malaysian Association of Bronchology and Interventional Pulmonology (MABIP). She is also the Adjunc. Prof for Lincoln University College based in Kota Bharu, Kelantan. 13
Dr Muhammad Adib Bin Abdul Onny NuclearMedicine Physician Depertment of Nuclear Medicine Institut Kanser Negara Dr. Muhammad Adib received his degree in Bachelor of Medicine & Surgery at UiTM in 2011. Later, he pursued postgraduate Master of Medicine in Nuclear Medicine in 2020 at Universiti Sains Malaysia. He is currently a Nuclear Medicine Physician at National Cancer Institute. He has been involved in innumerable publications and presentation, and has received many awards related or unrelated to his field. He also has been actively engaged in countless portfolio related to Nuclear Medicine, nationally. His research area and area of special interest are Dosimetry for radioiodine dose for benign thyroid disease and thyroid carcinoma, Thyroid cancer & management of thyroid cancer, PET-CT in Radiotherapy Planning and Comparison of 18 F-PSMA vs 68Ga-PSMA PET-CT in Prostate Carcinoma, A First in Malaysia Experience. Dr. Wan Fatihah is a Nuclear Medicine Physician of Universiti Sains Malaysia, Kelantan. She completed her Medical Degree at UNIMAS in 2006 followed by postgraduate Master of Medicine in Nuclear Medicine at AMDI Bertam in 2017. She is a member of Academy of Medicine of Malaysia, College of Radiology (CoR), Malaysia and Malaysian Society of Nuclear Medicine and Molecular Imaging. She is also a former head of department in Department of Nuclear Medicine, Radiotherapy and Oncology of HUSM since January 2019 until February 2023. She has been involved as Principle and Co-investigator in multiple research, as well as participate in numerous publication and oral or poster presentation. In addition, she is a Medical Lecturer and supervisor for undergraduate and postgraduate student of HUSM, Kelantan. Dr Wan Fatihah Binti Wan Sohaimi NuclearMedicine Physician/Lecturer Department of Nuclear Medicine, Radiotherapy & Oncology School of Medical Science USM 14
Assoc Prof Dr Norhafizah Mat Lazim obtained her MBBS from The University of Queensland, Australia in 1999, and completed Master of Otorhinolaryngology-Head and Neck Surgery from USM in 2012. She had Clinical Fellowship in Head and Neck Surgical oncology at Antoni van Leeuwenhoek–Netherland Cancer Institute (AVL-NKI) in 2014 and at VUMC, Free University Hospital, Amsterdam in 2015. In addition, she had clinical training at Sydney Head and Neck Cancer Institute, Chris O’Brien Lifehouse Australia, in 2019. She has a strong interest in head and neck surgical oncology. She acquired several national grants on head and neck diseases and tumors. She has in total of 100 publications in peer reviewed journals and several book chapters. She is a prominent reviewer for multiple international journals including Oral Oncology, PLoS One, IJPO and BMJ Case Report. She is a member of the American Head and Neck Society (AHNS), European Head and Neck Society (EHNS), Asian Head and Neck Oncology (ASHNO), American Thyroid Association (ATA), British Association Head and Neck Oncology (BAHNO), International Academy of Oral Oncology (IAOO) and Australian Institute of Medical Scientists (AIMS), International Federation of Head and Neck Oncology Society (IFHNOS), European Society of Translational Medicine (ESTM) and Australian Thyroid Foundation (ATF). She is the Malaysian coordinator for World Head and Neck Cancer Day under the umbrella of IFHNOS. Dr. Nisha received her undergraduate medical degree from University of Edinburgh, United Kingdom in 2010, and completed her Masters in Clinical Oncology at University Malaya in 2019 and is a fellow with the Royal College of Radiologists UK. She is now a clinical oncologist in University Malaya Medical Centre. Her sites of clinical interest are head and neck malignancies as well as paediatric radiation therapy. She has been actively involved in multiple research, publications and presentations. She is also currently a member of Malaysian Oncological Society (MCO), South-east Asian Radiation Oncology Group (SEAROG), European Society of Medical Oncology (ESMO) and European Society of Radiation Oncology (ESTRO) Dr Nisha Binti Mohd Shariff Consultant Clinical Oncologist University Malaya Medical Centre (UMMC) Assoc Prof Dr Norhafiza Binti Mat Lazim Consultant Head and Neck Surgeon/Lecturer Department of Otorhinolaryngology, School of Medical Science USM 15
Prof Wan Faisham is a faculty in the department of orthopedics, in School of Medical Sciences, Universiti Sains Malaysia. He has sub -specialized in musculoskeletal oncology and traumatology. Currently he is one of the leaders in the field of oncology applicable to sarcomas in Malaysia. He obtained his medical graduation from the National University of Malaysia (UKM) in 1994. Subsequently completed his post-graduation from Medical School of Universiti Sains Malaysia in year 2000. He is a Professor and consultant surgeon in USM; He is one of the pioneer’s member for limb salvage surgery for orthopedic cancer. He was involved with numerous clinical research and multidisciplinary collaboration in oncology. For his contributions he was awarded 5-distinguished awards and became the International advisor to Asian Pacific Musculoskeletal Oncology Society. Prof Faisham published more than 100 research papers in medical journals and 4 textbooks related to his field. He is also involved actively in management of c complex trauma and one of the national recourse persons for advanced trauma management. currently an active member of the school board in USM and a member of the examinations for the National Orthopedics Board. He is also recognized as orthopaedic oncology expert within Asean and Asia Pacific and trained more than 20 national and international orthopaedic oncology fellows. He has been serving Malaysian Orthopaedic Association as executive member for 6 years and became president of MOA in 2017. His research interest mainly focused on survival and functional outcome following surgery of orthopaedic cancer. The surgical method using allograft and vascularised tissue was recognized internationally as trademark of USMBasic science and proliferative marker growth of giant cell tumour of the bone is another area orthopaedic oncology unit USM champion. Prof Dr Wan Faisham Nu’man Bin Wan Ismail Consultant Orthopedic Surgeon/Lecturer Department of Orthopedic School of Medical Science USM Dr. Norazlina earned her undergraduate medical degree at Universiti Kebangsaan Malaysia in 2007 followed by postgraduate Master in Medicine in Nuclear Medicine at Universiti Sains Malaysia in 2014. She has been actively participating in National and International Conference and has received many awards national and internationally. She is now head of department for Nuclear Medicine, Radiotherapy and Oncology, HUSM. She is also a Medical Lecturer and involved in supervision of both undergraduate and postgraduate student of Universiti Sains Malaysia. At present, she has 3 ongoing research grants as primary investigator and co-investigator at national and university level, and 2 completed research grants as primary investigator and con-investigator at university level. Dr Norazlina Binti Mat Nawi NuclearMedicine Physician/Lecturer Department of Nuclear Medicine, Radiotherapy & Oncology School of Medical Science USM 16
Dr. Kamalia acquired her undergraduate degree of Doctor in Medicine at National University of Malaysia in 2004. She pursued postgraduate Master of Nuclear Medicine at University of Science Malaysia in 2014. She also a fellow of the Asian Nuclear Medicine Board (Shenyang) in 2016 and attained fellowship (Subspeciality) Training in Nuclear Neurology at Asan Medical Center, Seoul, South Korea in 2019-2020. She had 16 years of experience in Nuclear Medicine field (diagnostic & therapeutic) including 9 years of experience as Nuclear Medicine Physician with subspecialty in Nuclear Neurology. She has been actively joining multiple IAEA training since 2016 and involved in many national and international Conference presentations. Her latest publication was Therapy response of Yttrium-90 (Y-90) Colloid and Rhenium-186 (Re-186) Sulphur Colloid Radiosynovectomy in Hemophilic Arthropathy which was published on 8 June 2022 in Proceedings of Singapore Healthcare. She is now a Deputy Head of Department, Nuclear Medicine Department, Hospital KualaLumpur, Malaysia. She is also Member of World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Life Member of Malaysian Society of Nuclear Medicine and Molecular Imaging (MSNMMI), Executive committee member of Malaysian Society of Neurocognitive Clinical and Behavioural Imaging Initiative (NeuroCoB society), Member of National Specialist Registry (NSR) as a Nuclear Medicine Physician since 1st Jan 2018 and Member of Academy of Medicine of Malaysia and Member of Malaysian College of Radiology. Dr Kamalia Binti Kamarulzaman NuclearMedicine Physician Department of Nuclear Mediicine Hospital Kuala Lumpur Associate Professor Dr. Gokula studied medicine at Universiti Sains Mal aysia(USM) and pursued his 5-year specialist training under the Royal Australian and New Zealand College of Radiologists (RANZCR) Consultant Radiation Oncologist training programme at National University Hospital and Tan Tock Seng Hospital, Singapore and William Buckland Radiotherapy Centre, Alfred Health, Melbourne, Australia. He was awarded the Fellowship in Radiation Oncology (FRANZCR) by RANZCR in 2013. He is currently practising at few Oncology Centre including Advanced Medical and Dental Institute (AMDI), USM Hospital, Pantai Hospital Penang, Mount Miriam Cancer Hospital, KPJ Penang Specialist, Bagan Specialist Centre and Penang Adventist Hospital. His primary interest is in brachytherapy for the liver and tongue. The HyBIRT radiotherapy technique for tongue cancer is a novel treatment method developed by AMDI-USM team lead by Assoc Prof Dr. Gokula and the findings were presented as a proffered paper at ESTRO 2023. Assoc Prof Dr Gokula Kumar a/l Appalanaido Radiation Oncologist Pusat Perubatan USM Bertam (PPUSM) 17
SRI MAKMUR BALLROOM, LEVEL 3, H-ELITE DESIGN HOTEL AG- G -09 , ALWAQF @ TUNJONG, JALAN KUALA KRAI, 16010 KOTA BHARU, KELANTAN VENUE & LOCATION cOnference 18
PLAN floor 19
POSTER abstract OF 20
99mTc-Sestamibi Scintigraphy to Differentiate Benign and Malignant Renal Masses: A case report Muhammad Azizul Daud ,Khadijah Abdul Hamid ,Ezma Yanis Binti Mohd Mahidin , Nik A’isyah Binti Nik Mohd Zaid , Nurul Syamimi Binti Suhaimi , Wan Fatihah Wan Sohaimi Introduction: The incidental finding renal masses on imaging has consistently increased. Anatomical imaging is restricted in their capacity to differentiate benign from malignant renal masses. Renal mass biopsy has a high non-diagnostic rate, poor negative-predictive ability and potential risks along with significant costs. Benign renal masses are frequently unwarranted resected for the misleading assumption of malignant growth. 99mTc-sestamibi SPECT/CT is a molecular imaging test that considers the separation of benign renal oncocytomas from malignant renal cell carcinomas (RCCs). Report: A 61-year-old male presented with lower urinary tract symptoms associated with lethargy and vomiting. After imaging evaluations in 4 to 6 months apart with ultrasoundKUB, CT urography and CT renal 4-phase scan, there was persistent isodense rena llesion in the right lower pole. Repeated CT renal 4-phase revealed a rounded, soft tissue lesion in the right lower pole which appeared larger (Fig.1) Renal 99mTc-sestamibi scan was requested and showed absent of tracer uptake at the right lower pole corresponds to soft tissue lesion in the CT renal 4-phase prior (Fig. 2). This soft tissue lesion with no sestamibi avidity is suspicious for malignancy. Conclusion: The result highlights a potential role for 99mTc-sestamibi SPECT/CT in the evaluation of benign and malignant renal masses. Oncocytoma cells are loaded with normal-appearing mitochondria with high affinity of 99mTc-sestamibi. RCCs have been exhibited to contain diminished measures of some mitochondrial proteins in contrast with the normal kidney, which reflect to reduce or absent of 99mTc-sestamibi take up in the cells.A non-invasive assessment of patients with solid enhancing renal masses with simple imaging study using 99mTc-sestamibi may be able to pre-operatively identify those patients harboring an oncocytoma, thus sparing them from unnecessary surgery. Advance Medical and Dental Institute (AMDI), Bertam, Kepala Batas, Pulau Pinang. Department of Nuclear Medicine, Radiotherapy & Oncology, Hospital Universiti Sains Malaysia (Hosp USM), Kubang Kerian, Kelantan. Department of Nuclear Medicine, Radiotherapy & Oncology, School of Medical Science, Universiti Sains Malaysia (USM), Kubang Kerian, Kelantan. 1. 2. 3. 1,2 1 2 2 2 2,3 21
A Positive Outcome. IKN First Promising Experience in MIBG Therapy for Advanced Inoperable Functioning Paraganglioma. SitiFazira Edzua binti Jamaludin , NurFadzelah Mokhtar , Muhammad Adib Abdul Onny , Nor Salita Ali Introduction: Meta-iodo-benzyl-guanidine(MIBG) is an analogue of guanethidine and substrate of the norepinephrine transporter which localized intra-cellularly. Radioiodinelabelled MIBG is a useful theragnostic agent, commonly used in the assessment as well as for therapeutic intent in neuroectodermal tumours such as paraganglioma and pheochromocytoma. I-123 is the preferred agent for diagnostic purposes but due to its unavailability in Malaysia, I-131 is used for both diagnostic and therapeutic intent. I-131 MIBG therapy is indicated for inoperable and stage III-IV neuroblastoma, paraganglioma and pheochromocytoma with objective response rate seen in up to 46% of cases. Furthermore, stabilization of tumor volume and partial hormonal are seen in more than 50% and 40% respectively which in turn led to improvement of clinical symptoms and reduction in reliance on medications. Case Description: Herein, we present a case of a 47-year-old woman with a recurrent functioning paraganglioma with liver, lymph nodes and lungs metastases. Despite re-debulking surgery, she showed persistent symptoms, including vomiting and uncontrolled hypertension. She proceeded with 4 cycles of I-131 MIBG therapy with total cumulative dose of 739 mCi. She experienced bouts of hypotensive and hypertensive episodes during the course of therapy as well as reversible haematological toxicities but overall tolerated the therapy well. Interestingly, post 4-cycles, she showed good overall response with urine metanephrine showed a significant reduction accompanied by a significant improvement in blood pressure control and a decrease in symptoms. Conclusion: This case report highlights the effectiveness of MIBG therapy in reducing urine catecholamine levels and improving clinical symptoms in patients with metastatic paragangliomas. 1.Nuclear Medicine Department, Institut Kanser Negara, 62250, W.P. Putrajaya. 221 1 1 1
Correlation between blood- and red marrow- absorbed dose estimated for radioiodine therapy surrogated by Iodine-124 Marianie Musarudin , Boo Shu Teng, Mohamad Aminudin Said Introduction: Pre-therapeutic dosimetry of radioiodine (131I) therapy doses to treat differentiated thyroid cancer (DTC) offers effective personalized maximum tolerable activity (MTA) of 131I by estimating and ensuring that the resulting blood- or red marrow- absorbed dose ( or ) was within 2 Gy to prevent myelotoxicity. To date, our institution has implemented the EANM blood-based dosimetry model for estimation. This study aimed to assess the correlation and compare it with the RM- based dosimetry models. Material & Method: The demographic and dosimetric data of 65 adult DTC patients who underwent the pretherapeutic blood-based dosimetry assessment of 131I therapy were retrieved. The RMbased dosimetry models included were the EANM-modified model, the Single Measurement Model (SMM), the Italian Association of Medical Physics (AIFM), Traino, and OLINDA/EXM version 1.1. Result: Significant, strong, and positive relationships were observed between the and computed by the RM-based dosimetry models (r=0.640 to r=0.988, p<0.001), with the strongest correlation demonstrated by the Traino model. However, the median was proven to be statistically significant different and higher than the calculated by RMbased dosimetry models (p<0.001 to 0.007). Conclusion: The RM-based dosimetry models were proven to have excellent correlation with the standard blood model, except for SMM (r=0.640). Other models, particularly Traino, are highly recommended as alternatives for the resulting dose of ≤15 mGy. However, it is suggested that the EANM blood-based dosimetry model should be retained as the standard formalism in all circumstances, owing to its conservative personalized MTA, which ensure radiation safety. School of Health Sciences, Universiti Sains Malaysia, Kelantan. Department of Nuclear Medicine, Institut Kanser Negara, Putrajaya. 1. 2. 231 1 2
SPONSORS the 24
gold SPONSORS FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. +603-76243888 http://www.astrazeneca.com/malaysia
gold SPONSORS FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. Formally established in 1941 and headquartered in Tokyo, Japan. Eisai has since grown to become a leading global research and development-base pharmaceutical company, operating over 40 subsidiaries and employing more than 10,000 employees wordwide. We specialist in primary care, central nervous system and Oncology disease area. https://eisaimal.com/contact-us/
silver SPONSORS FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. We specialize in improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. +603-22026999 http://www.astellas.com/my/contact-us
Report any adverse events to Astellas Pharma Malaysia Sdn.Bhd. at [email protected] For Healthcare Professionals Only Astellas Pharma Malaysia Sdn Bhd Suite 1805,Level 18, CenterPoint North Tower, Mid Valley City,Lingkaran Syed Putra, 59200 Kuala Lumpur. Tel: +603-22026999 Fax: +603-2202 6988, +603-2202 6977www.astellas.com MAT-MY-XTD-2023-00040 SEP 2023 References: 1.Armstrong AJet al. JClin Oncol2019;37(32):2974–2986. 2.Armstrong AJet al. JClin Oncol2022;40(15):1616–1622. 3.XTANDI(Enzalutamide)Malaysia Full PrescribingInformation revised 24082022. 4. HussaineMt al. N Engl JMed2018;378(26):2465–2474. XTANDI (enzalutamide) is indicated for the treatment of adult men with: mHSPC in combination with ADT; high-risk nmCRPC; mCRPC who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; mCRPC whose disease has progressed on or after docetaxel therapy. *ARCHES was a multinational, double-blind, randomised, placebo-controlled phase III study comparing the efficacy and safety profile of XTANDI + ADT vs placebo + ADT in 1,150 men with mHSPC. The primary endpoint was rPFS and OS was a key secondary endpoint. These data are from the ARCHES final analysis (data cutoff date of 28 May 2021). Following the primary analysis, the study was unblinded to allow patients on placebo + ADT to cross over to XTANDI + ADT in an open-label extension study. High risk is defined as patients with rising PSA despite castration-associated testosterone levels, with ≥3 rising PSA levels ≥1 week apart, a baseline PSA level ≥2 ng/ml and a PSA doubling time of ≤10 months. ADT=androgen deprivation therapy; AE=adverse event; mCRPC=metastatic castration-resistant prostate cancer; mHSPC=metastatic hormone-sensitive prostate cancer; nmCRPC=non-metastatic castration-resistant prostate cancer; OS=overall survival; PSA=prostate-specific antigen; rPFS=radiographic progression-free survival. Scan here for XTANDITM Malaysia Full Prescribing Information 1,2 2 4 ‡ 3 † ‡
silver SPONSORS FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. At Pfizer, patients are at the heart of all that we do. Developing breakthroughs that change patients’ lives is not just a goal, it is our very purpose. We specialize in Medicine Safety, Inflammatory & Immunology, Anti Infectives, Oncology, Rare Disease, Vaccines, Internal Medicine and Mental Health. +603-22816000 http://www.pfizer.com.my/connect-with-us
FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. +603-76827777 http://www.novartis.com/my-en/
FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. Eunice Chong <[email protected]>
FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. We specialize in surgical microscope and Intraoperative Radiotheraphy (IORT). [email protected]
FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS. MEDILIANCE (M) SDN BHD 03-7955 2373
ALATAN TEKNOLOGI SDN BHD FOR YOUR CONTRIBUTION TO MAKE THIS PROGRAM A SUCCESS.